HPV testing as a screen for cervical cancer

BMJ. 2015 Jun 30:350:h2372. doi: 10.1136/bmj.h2372.

Abstract

Human papillomavirus (HPV) has been identified as a necessary factor in the development of pre-invasive and invasive cancers of the lower genital tract, of which cervical cancer is the most prevalent. A molecular understanding of malignant transformation and epidemiologic information has led to the development of many strategies for detection and early intervention. Newer tests for oncogenic subtypes of HPV have made it possible to predict the risk of future development of cervical cancer. This review summarizes the current understanding of HPV related disease and examines the role of HPV testing as a screening tool for cervical cancer. It summarizes the data from prospective and randomized controlled trials on HPV screening from Europe and North America and includes smaller studies from low and middle income countries where cervical cancer is the most common cancer in women.

Publication types

  • Review

MeSH terms

  • Early Detection of Cancer* / methods
  • Female
  • Humans
  • Incidence
  • Mass Screening* / methods
  • Papillomaviridae / classification
  • Papillomavirus Infections / diagnosis*
  • Papillomavirus Infections / epidemiology
  • Prevalence
  • Uterine Cervical Dysplasia / diagnosis
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / virology*